Combined Simulation and Mutagenesis Analyses Reveal the Involvement of Key Residues for Peroxisome Proliferator-activated Receptorα Helix 12 Dynamic Behavior*

The dynamic properties of helix 12 in the ligand binding domain of nuclear receptors are a major determinant of AF-2 domain activity. We investigated the molecular and structural basis of helix 12 mobility, as well as the involvement of individual residues with regard to peroxisome proliferator-activated receptor α (PPARα) constitutive and ligand-dependent transcriptional activity. Functional assays of the activity of PPARα helix 12 mutants were combined with free energy molecular dynamics simulations. The agreement between the results from these approaches allows us to make robust claims concerning the mechanisms that govern helix 12 functions. Our data support a model in which PPARα helix 12 transiently adopts a relatively stable active conformation even in the absence of a ligand. This conformation provides the interface for the recruitment of a coactivator and results in constitutive activity. The receptor agonists stabilize this conformation and increase PPARα transcription activation potential. Finally, we disclose important functions of residues in PPARα AF-2, which determine the positioning of helix 12 in the active conformation in the absence of a ligand. Substitution of these residues suppresses PPARα constitutive activity, without changing PPARα ligand-dependent activation potential.

[1]  L. Moore,et al.  Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Markus Meuwly,et al.  Study of the insulin dimerization: Binding free energy calculations and per‐residue free energy decomposition , 2005, Proteins.

[3]  Ping-Chiang Lyu,et al.  Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists. , 2007, Journal of medicinal chemistry.

[4]  W. Wahli,et al.  PPARα Structure-Function Relationships Derived from Species-Specific Differences in Responsiveness to Hypolipidemic Agents , 1997, Biological chemistry.

[5]  J. Auwerx,et al.  p300 Interacts with the N- and C-terminal Part of PPARγ2 in a Ligand-independent and -dependent Manner, Respectively* , 1999, The Journal of Biological Chemistry.

[6]  W. C. Still,et al.  Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .

[7]  D. Case,et al.  Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. , 2003, Journal of molecular biology.

[8]  Hoover,et al.  Canonical dynamics: Equilibrium phase-space distributions. , 1985, Physical review. A, General physics.

[9]  M. Karplus,et al.  Simulation of activation free energies in molecular systems , 1996 .

[10]  W. Wahli,et al.  Involvement of PPAR nuclear receptors in tissue injury and wound repair. , 2006, The Journal of clinical investigation.

[11]  T. Willson,et al.  Peroxisome proliferator activated receptor agonists. , 1997, EXS.

[12]  J. Schwabe,et al.  Mechanism of the nuclear receptor molecular switch. , 2004, Trends in biochemical sciences.

[13]  Terry K. Smith,et al.  Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids. , 2006, Journal of molecular biology.

[14]  José M Bautista,et al.  Three Peroxisome Proliferator-activated Receptor Isotypes from Each of Two Species of Marine Fish , 2022 .

[15]  N. Blomberg,et al.  Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family , 2001 .

[16]  V. Chatterjee,et al.  Functional analysis of a transactivation domain in the thyroid hormone beta receptor. , 1994, The Journal of biological chemistry.

[17]  R. DesJarlais,et al.  Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere. , 1994, Journal of medicinal chemistry.

[18]  L. Jendeberg,et al.  Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor PPARγ* , 1998, The Journal of Biological Chemistry.

[19]  Olivier Poch,et al.  Signature of the oligomeric behaviour of nuclear receptors at the sequence and structural level , 2004, EMBO reports.

[20]  P E Bourne,et al.  The Protein Data Bank. , 2002, Nucleic acids research.

[21]  D. Moras,et al.  Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. , 2002, Molecular cell.

[22]  Bin He,et al.  Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. , 2004, Molecular cell.

[23]  Hans Peter Märki,et al.  Structure-based design of indole propionic acids as novel PPARα/γ co-agonists , 2006 .

[24]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[25]  Satoshi Yasuda,et al.  Different Residues Mediate Recognition of 1-O-Oleyllysophosphatidic Acid and Rosiglitazone in the Ligand Binding Domain of Peroxisome Proliferator-activated Receptor γ* , 2006, Journal of Biological Chemistry.

[26]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[27]  W. C. Still,et al.  A rapid approximation to the solvent accessible surface areas of atoms , 1988 .

[28]  Xiaohong Liu,et al.  Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors , 2003, Nature.

[29]  William Bourguet,et al.  Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α , 1995, Nature.

[30]  C. Carlberg,et al.  The critical role of carboxy-terminal amino acids in ligand-dependent and -independent transactivation of the constitutive androstane receptor. , 2003, Molecular endocrinology.

[31]  T. Halgren Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions , 1996 .

[32]  B. M. Forman,et al.  A Structural Model of the Constitutive Androstane Receptor Defines Novel Interactions That Mediate Ligand-Independent Activity , 2002, Molecular and Cellular Biology.

[33]  J. Girard,et al.  Phosphorylation of PPARs: from molecular characterization to physiological relevance. , 2005, Biochimie.

[34]  M. Lazar,et al.  A Dominant-negative Peroxisome Proliferator-activated Receptor γ (PPARγ) Mutant Is a Constitutive Repressor and Inhibits PPARγ-mediated Adipogenesis* , 2000, The Journal of Biological Chemistry.

[35]  Charles L. Brooks,et al.  Generalized born model with a simple smoothing function , 2003, J. Comput. Chem..

[36]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[37]  B. Brooks,et al.  Constant pressure molecular dynamics simulation: The Langevin piston method , 1995 .

[38]  Béatrice Desvergne,et al.  Peroxisome-proliferator-activated receptors and cancers: complex stories , 2004, Nature Reviews Cancer.

[39]  J. Schwabe,et al.  A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease , 2003, Nature Structural Biology.

[40]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[41]  Kendall W Nettles,et al.  Ligand control of coregulator recruitment to nuclear receptors. , 2005, Annual review of physiology.

[42]  Peter J. Brown,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .

[43]  J. Lehmann,et al.  Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. , 2000, Molecular cell.

[44]  Charles L. Brooks,et al.  New analytic approximation to the standard molecular volume definition and its application to generalized Born calculations , 2003, J. Comput. Chem..

[45]  T. Halgren Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[46]  C. Carlberg,et al.  Agonist-dependent and Agonist-independent Transactivations of the Human Constitutive Androstane Receptor Are Modulated by Specific Amino Acid Pairs* , 2004, Journal of Biological Chemistry.

[47]  Jean-Paul Renaud,et al.  Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.

[48]  I. Lu,et al.  Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. , 2006, Journal of medicinal chemistry.

[49]  D. Moore,et al.  A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements , 1994, Molecular and cellular biology.

[50]  Samuel H. Yalkowsky,et al.  Solubility of nonelectrolytes in polar solvents. V. Estimation of the solubility of aliphatic monofunctional compounds in water using a molecular surface area approach , 1975 .

[51]  M. Lazar,et al.  Interdomain communication regulating ligand binding by PPAR-γ , 1998, Nature.

[52]  Millard H. Lambert,et al.  Asymmetry in the PPARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors , 2000 .

[53]  J. Berger,et al.  PPARs: therapeutic targets for metabolic disease. , 2005, Trends in pharmacological sciences.

[54]  W. Wahli,et al.  Be fit or be sick: peroxisome proliferator-activated receptors are down the road. , 2004, Molecular endocrinology.

[55]  S. O’Rahilly,et al.  Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.

[56]  Christine Dreyer,et al.  Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.

[57]  Thomas A. Kunkel,et al.  Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[58]  D. Waxman,et al.  STAT5b Down-regulates Peroxisome Proliferator-activated Receptor α Transcription by Inhibition of Ligand-independent Activation Function Region-1trans-Activation Domain* , 1999, The Journal of Biological Chemistry.

[59]  D. Barettino,et al.  Characterization of the ligand‐dependent transactivation domain of thyroid hormone receptor. , 1994, The EMBO journal.

[60]  E. Purisima,et al.  Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity. , 2006, Human molecular genetics.

[61]  R G Smith,et al.  Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. , 2000, Journal of molecular biology.

[62]  Terry K. Smith,et al.  Reevaluation of the PPAR-β/δ Ligand Binding Domain Model Reveals Why It Exhibits the Activated Form , 2006 .

[63]  P. Kushner,et al.  Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. , 1995, The EMBO journal.

[64]  Béatrice Desvergne,et al.  From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. , 2006, Progress in lipid research.

[65]  Robert B. Hermann,et al.  Theory of hydrophobic bonding. II. Correlation of hydrocarbon solubility in water with solvent cavity surface area , 1972 .

[66]  C. Carlberg,et al.  Structural Determinants of the Agonist-independent Association of Human Peroxisome Proliferator-activated Receptors with Coactivators* , 2005, Journal of Biological Chemistry.

[67]  Markus Meuwly,et al.  Importance of individual side chains for the stability of a protein fold: Computational alanine scanning of the insulin monomer , 2006, J. Comput. Chem..

[68]  A. Burger,et al.  Regulation of the Transcriptional Activity of the Peroxisome Proliferator-activated Receptor α by Phosphorylation of a Ligand-independent trans-Activating Domain* , 1999, The Journal of Biological Chemistry.

[69]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[70]  K. Umesono,et al.  A Unified Nomenclature System for the Nuclear Receptor Superfamily , 1999, Cell.

[71]  P. Chambon,et al.  Activation function 2 (AF‐2) of retinoic acid receptor and 9‐cis retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF‐2 activity. , 1994, The EMBO journal.

[72]  W. Wahli,et al.  Kinase signaling cascades that modulate peroxisome proliferator-activated receptors. , 2005, Current opinion in cell biology.

[73]  C. Brooks,et al.  Novel generalized Born methods , 2002 .

[74]  Thomas A. Halgren,et al.  Merck molecular force field. IV. conformational energies and geometries for MMFF94 , 1996 .

[75]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[76]  D. Moras,et al.  Structural studies on nuclear receptors , 2000, Cellular and Molecular Life Sciences CMLS.

[77]  P. Chambon,et al.  Suprabasal expression of a dominant-negative RXR alpha mutant in transgenic mouse epidermis impairs regulation of gene transcription and basal keratinocyte proliferation by RAR-selective retinoids. , 1997, Genes & development.

[78]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[79]  Kaixian Chen,et al.  Binding analyses between Human PPARgamma-LBD and ligands. , 2004, European journal of biochemistry.

[80]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[81]  Thomas A. Halgren,et al.  Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94 , 1996, J. Comput. Chem..

[82]  T. Halgren,et al.  Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules , 1996 .

[83]  Y. Kong,et al.  Dynamic inhibition of nuclear receptor activation by corepressor binding. , 2003, Molecular endocrinology.